Cover Image

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study

Saved in:

Bibliographic Details
Main Authors:	McCann L (Author), Ozdogan H (Author), Rutkowska-Sak L (Author), Ferrandiz MA (Author), Wulffraat NM (Author), Brik R (Author), Kallinich T (Author), Erguven M (Author), Berkun Y (Author), Constantin T (Author), Quartier P (Author), Horneff G (Author), Brunner H (Author), Ruperto N (Author), Lheritier K (Author), Preiss R (Author), Tseng L (Author), Martini A (Author), Lovell DJ (Author)
Format:	Book
Published:	BMC, 2011-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
by: Ruperto N, et al.
Published: (2008)

Experience of the Successful Treatment With Canakinumab of a Patient With Systemic Juvenile Idiopathic Arthritis
by: Ekaterina I. Alexeeva, et al.
Published: (2017)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
by: Takada H, et al.
Published: (2011)

Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience
by: Lingzhi Qiu, et al.
Published: (2024)

CLINICAL CASE OF CANAKINUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: R. V. Denisova, et al.
Published: (2013)

Subclinical TRAPS treated with canakinumab
by: M. Amatruda, et al.
Published: (2021)

Canakinumab in the treatment of systemic juvenile idiopathic arthritis: a retrospective single center study in China
by: Xiaona Zhu, et al.
Published: (2024)

The clinical course and long-term outcome of juvenile systemic lupus erythematosus
by: Wierzbowska M, et al.
Published: (2008)

Treatment of refractory Yao syndrome with canakinumab
by: Caroline J. Brailsford, MS, et al.
Published: (2022)

CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
by: Ye. I. Alekseeva, et al.
Published: (2014)

Could canakinumab be used for COVID-19?
by: V. A. Otdelenov, et al.
Published: (2020)

The journey of canakinumab; on- and off-label indications
by: Daniela Marotto, et al.
Published: (2019)

CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS
by: E. I. Alexeeva, et al.
Published: (2014)

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis
by: Mikhail M. Kostik, et al.
Published: (2022)

Canakinumab and cardiovascular outcomes: results of the CANTOS trial
by: Syed Raza Shah, et al.
Published: (2018)

Administration of the Interleukin-1 Inhibitor Canakinumab in Children with Autoinflammatory Diseases and Systemic Juvenile Arthritis: the Report for Case Series
by: S. O. Salugina, et al.
Published: (2016)

EXPERIENCE OF THE SUCCESSFUL CANAKINUMAB TREATMENT OF A PATIENT WITH UNDIFFERENTIATED AUTOINFLAMMATORY SYNDROME
by: Tatyana V. Sleptsova, et al.
Published: (2016)

Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab
by: Angel Luis Salcedo-Mingoarranz, et al.
Published: (2023)

Modulation of Inflammation in Heart Failure: The Role of Ziltivekimab and Canakinumab
by: Łukasz Wołowiec, et al.
Published: (2024)

Development and Role in Therapy of Canakinumab in Adult-Onset Still's Disease
by: Paola Galozzi, et al.
Published: (2018)

Harnessing the immune system in the battle against breast cancer
by: Elizabeth S Nakasone, et al.
Published: (2018)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
by: Espada G, et al.
Published: (2011)

Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment
by: Alpa M, et al.
Published: (2015)

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
by: Burcu Bozkaya Yücel, et al.
Published: (2021)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
by: Martini A, et al.
Published: (2011)

Experience of the successful treatment with canakinumab of a patient with NLPC4-associated autoinflammatory syndrome with enterocolitis
by: T. V. Sleptsova, et al.
Published: (2016)

Juvenile idiopathic arthritis with systemic onset with inflammatory bone lesions: two case reports of patients successfully treated with canakinumab and experience gained from literature
by: Ekaterina I. Alexeeva, et al.
Published: (2023)

EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID)
by: T. V. Sleptsova, et al.
Published: (2014)

Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases
by: Riccardo Papa, et al.
Published: (2020)

Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease
by: Antonio Vitale, et al.
Published: (2020)

A retrospective clinical analysis of medical treatments used for symptomatic relief of Raynaud's phenomenon in children at Royal Liverpool Children's Hospital, UK
by: Gargh K, et al.
Published: (2008)

Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China
by: Xiaona Zhu, et al.
Published: (2024)

Efficacy of Pneumococcal Polysaccharide Conjugate Vaccine (13-valent, Adsorbed) in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Genetically Engineered Biologic Drugs (Tocilizumab or Canakinumab): Prospective Cohort Study
by: Ekaterina I. Alexeeva, et al.
Published: (2020)

Two Sisters with Colchicine-Resistant form of Familial Mediterranean Fever on the Canakinumab Therapy: Clinical Case
by: Elena A. Ligostaeva, et al.
Published: (2020)

The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
by: Kacar M, et al.
Published: (2020)

Atherosclerosis in Juvenile Idiopathic Arthritis
by: Ewa Jednacz, et al.
Published: (2012)

Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept
by: Ruperto N, et al.
Published: (2008)

Treating TRAPS Syndrome with a Previously Undescribed TNF α Gene Receptor Mutation Successfully with Canakinumab
by: T. V. Sleptsova, et al.
Published: (2016)

Factors Associated with the Development of Adrenal Insufficiency in Patients with Juvenile Idiopathic Arthritis Who Received Systemic Corticosteroids
by: Gizem Zengin Ersoy, et al.
Published: (2023)

Abatacept treatment improves health-related quality of life, pain, and sleep quality in juvenile idiopathic arthritis patients
by: Ruperto N, et al.
Published: (2008)